NWU Institutional Repository

Solution-mediated crystallization of amorphous azithromycin

dc.contributor.authorStieger, N.
dc.contributor.authorJoubert, A.
dc.contributor.authorLiebenberg, W.
dc.contributor.researchID12038156 - Stieger, Nicole
dc.contributor.researchID10196226 - Liebenberg, Wilna
dc.contributor.researchID11781963 - Joubert, André
dc.date.accessioned2017-07-27T07:09:19Z
dc.date.available2017-07-27T07:09:19Z
dc.date.issued2017
dc.description.abstractWater and water vapor are the bane of amorphous drug stability, both in storage and after administration. As is to be expected, crystallization of amorphous azithromycin did occur when exposed to water as dissolution medium. However, experimental results showed that, although solution-mediated phase transformation had occurred, it was not a rapid process for this drug. It is considered to be an advantageous characteristic of amorphous azithromycin and likely due to the high molecular mass (748.984 g/mol) and complex structure necessitating more energy for transformations to occur. A high apparent solubility is maintained for a considerable period of time, potentially rendering a higher percentage of this BCS Class II drug available for absorption when administered orallyen_US
dc.identifier.citationStieger, N. et al. 2017. Solution-mediated crystallization of amorphous azithromycin . Die Pharmazie, 72(8):447-448. [https://doi.org/10.1691/ph.2017.7035]en_US
dc.identifier.issn0031-7144
dc.identifier.urihttp://hdl.handle.net/10394/25220
dc.identifier.urihttp://www.ingentaconnect.com/contentone/govi/pharmaz/2017/00000072/00000008/art00003
dc.identifier.urihttps://doi.org/10.1691/ph.2017.7035
dc.language.isoenen_US
dc.publisherAvoxaen_US
dc.titleSolution-mediated crystallization of amorphous azithromycinen_US
dc.typeArticleen_US

Files

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.61 KB
Format:
Item-specific license agreed upon to submission
Description: